Lomitapide affects HDL composition and function

6533b855fe1ef96bd12afdce

RESEARCH PRODUCT

Lomitapide affects HDL composition and function

J.e. Roeters Van Lennep Monique T. Mulder Maria Pia Adorni Laura Calabresi Angelo B. Cefalù Franco Bernini R. Yahya Eric J.g. Sijbrands Elda Favari Monica Gomaraschi Maurizio Averna Adrie J.m. Verhoeven Francesca Zimetti

subject

Adult Male 0301 basic medicine medicine.medical_specialty Settore MED/09 - Medicina Interna HDL Homozygous familial hypercholesterolemia Familial hypercholesterolemia 030204 cardiovascular system & hematology Hyperlipoproteinemia Type II Young Adult 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine Humans Medicine In patient Clinical efficacy Hyperlipoproteinemia Type II Cholesterol business.industry Cholesterol HDL Homozygote nutritional and metabolic diseases Cholesterol LDL Cholesterol efflux capacity Atherosclerosis medicine.disease Cholesterol lowering drugs Lomitapide Lomitapide Cholesterol Phenotype Treatment Outcome 030104 developmental biology Endocrinology chemistry Benzimidazoles Female lipids (amino acids peptides and proteins)Composition (visual arts)Cholesterol lowering drug Hydroxymethylglutaryl-CoA Reductase Inhibitors Lipoproteins HDL Cardiology and Cardiovascular Medicine business ATP Binding Cassette Transporter 1

description

Abstract Background Lomitapide reduces low-density lipoprotein-cholesterol (LDL-C) but also high-density lipoprotein-cholesterol (HDL-C) levels. The latter may reduce the clinical efficacy of lomitapide. We investigated the effect of lomitapide on HDL-C levels and on cholesterol efflux capacity (CEC) of HDL in patients with homozygous familial hypercholesterolemia (HoFH). Methods and results Four HoFH patients were treated with increasing dosages of lomitapide. Lomitapide decreased LDL-C (range −34 to −89%). Total HDL-C levels decreased (range −16 to −34%) with a shift to buoyant HDL. ABCA1-mediated CEC decreased in all patients (range −39 to −99%). The changes of total, ABCG1- and SR-BI-mediated CEC were less consistent. Conclusion Lomitapide decreased LDL-C and HDL-C levels. Our report raises the hypothesis that the anti-atherogenic potential of HDL seems to be unaffected as total CEC did not seem to change consistently. Combined with the reduction of atherogenic lipoproteins, the net effect of lomitapide appears to be beneficial in HoFH patients.

year	journal	country	edition	language
2016-08-01	Atherosclerosis

10.1016/j.atherosclerosis.2016.05.005 https://doi.org/10.1016/j.atherosclerosis.2016.05.005